TransCode Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $27.50 on 10/16/23, while the lowest price for the same period was registered at $0.22 on 08/14/24.
52-week price history of RNAZ Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. TransCode Therapeutics Inc’s current trading price is -97.92% away from its 52-week high, while its distance from the 52-week low is 164.35%. The stock’s price range during the 52-week period has remained between $0.22 and $27.50. In the Healthcare sector, the company’s shares saw a trading volume of around 0.91 million for the day, which was evidently lower than the average daily volume of 1.82 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly decline of -40.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 9.86M and boasts a workforce of 10 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7184, with a change in price of -0.5890. Similarly, TransCode Therapeutics Inc recorded 1,737,550 in trading volume during the last 100 days, posting a change of -50.78%.
Examining RNAZ’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
TransCode Therapeutics Inc’s raw stochastic average for the past 50 days is presently 56.89%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 68.66%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 76.38% and 82.13%, respectively.
RNAZ Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -91.34% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -17.49%. Over the past 30 days, the price of RNAZ has fallen by 104.81%. And in the last five days, it has surged by 85.93%.
